The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The impact of high and low burden TP53 mutations on risk and treatment decision in CLL
Maher Salamoon, MD, Al-Baironi Hospital, Damascus, Syria, discusses the impact of TP53 mutations on risk stratification and treatment decisions in newly diagnosed chronic lymphocytic leukemia (CLL). High-burden TP53 mutations correlate with poor outcomes and reduced drug response. Chemoimmunotherapy is now avoided in these patients; alternatives include ibrutinib, or venetoclax plus obinutuzumab. Early TP53 testing by next-generation sequencing (NGS) at diagnosis is recommended for all patients with CLL to guide treatment approaches. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
